Tenofovir: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Caesar Schinas
m (Bot: Replacing medical templates with CZMed)
imported>Robert Badgett
No edit summary
Line 32: Line 32:
* Apropovir  
* Apropovir  
* Viread  
* Viread  
==History==
Viread brand of tenofovir was approved for Gilead Sciences by the [[Food and Drug Administration]] in the [[United States]] with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) in 2001.<ref>{{FDA-Drug_Details|021356}}</ref>
A generic version with a AB [[Food and Drug  Administration/Catalogs/Therapeutic Equivalence Code|Therapeutic Equivalence Code]] was approved for Cipla Limited with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2009.<ref>{{FDA-Drug_Details|078800}}</ref> The generic ANDA was reviewed under the expedited review provisions of the President’s Emergency Plan for AIDS Relief (PEPFAR) with the agreement that the drug would not be marketed in the United States until the Viread patent protection expires in 2017.
==References==
<references/>
   
   
== External links ==
== External links ==
{{CZMed}}
{{CZMed}}

Revision as of 20:50, 29 January 2013

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
Tenofovir structure.jpg
tenofovir
IUPAC name: see chemistry section
Synonyms: TDF, PMPA
Formula: C9H14N5O4P

 Uses: HIV/AIDS & Hep. B

 Properties: RT inhibitor, adenosine analog

 Hazards: see drug interactions

Mass (g/mol): CAS #:
287.2123 147127-20-6


Tenofovir is a nucleotide analog reverse transcritase inhibitor (nRTI) antiviral drug used to treat HIV/AIDS and is in clinical trials for treatment of hepatitis B infection. The triphosphate from of the drug competes with the natural DNA nucleotide deoxyadenosine triphosphate (dATP) during DNA formation and it acts as a DNA chain terminator once incorporated because it lacks the normal deoxyribose sugar needed for connecting to the next DNA base.

Chemistry

The IUPAC chemical name for tenofovir is [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid and it has chemical formula C9H14N5O4P, giving it a molecular mass of 287.2123 g/mol. It is chemically similar to the natural neucleotide adenosine but lacks a ribose sugar unit.

Synonyms and brand names

Synonyms

  • Tenofovir disoproxil
  • Tenofovir disoproxil fumarate
  • D,L-Tenofovir
  • TDF
  • PMPA

Brand Names

  • Apropovir
  • Viread

History

Viread brand of tenofovir was approved for Gilead Sciences by the Food and Drug Administration in the United States with a New Drug Application (NDA) in 2001.[1]

A generic version with a AB Therapeutic Equivalence Code was approved for Cipla Limited with a Abbreviated New Drug Application (ANDA) in 2009.[2] The generic ANDA was reviewed under the expedited review provisions of the President’s Emergency Plan for AIDS Relief (PEPFAR) with the agreement that the drug would not be marketed in the United States until the Viread patent protection expires in 2017.


References

  1. Anonymous. Drugs@FDA for FDA Application No. 021356. U S Food and Drug Administration
  2. Anonymous. Drugs@FDA for FDA Application No. 078800. U S Food and Drug Administration

External links

The most up-to-date information about Tenofovir and other drugs can be found at the following sites.